Clinical Trials Logo

Clinical Trial Summary

This is a randomised controlled trial aimed at comparing the efficacy of levonorgestrel (LNG) co-administered with piroxicam or placebo for oral emergency contraception (EC). Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) commonly used as a pain-killer in inflammatory conditions. Efficacy will be measured as the percentage of pregnancies prevented.


Clinical Trial Description

Objective: To compare the percentage of pregnancies prevented by LNG co-administered with piroxicam or placebo for oral emergency contraception (EC) by a randomised controlled trial. Hypothesis to be tested: LNG plus piroxicam has higher percentage of pregnancies prevented compared with LNG plus placebo for oral emergency contraception. Design and subjects: This will be a prospective, randomised placebo-controlled clinical trial. Women attending the Family Planning Association of Hong Kong for oral EC within 72 hours of unprotected sexual intercourse will be recruited. Study instruments: Prospective follow-up of subjects in the clinic for the primary and secondary outcomes. Interventions: Eligible subjects will be randomised to receive one of the two treatment regimens, i.e. Group A: a single dose of LNG 1.5 mg and piroxicam 40 mg, or Group B: a single dose of LNG 1.5mg and placebo under direct supervision. Main outcome measures: Percentage of pregnancies prevented (PPP) is the primary outcome measure. Secondary outcome measures include failure rate, rate of occurrence of side effects and pattern of the menstruation following EC. Data analysis:The percentage of pregnancies prevented, failure rate and rate of occurrence of side effects will be compared between groups using Fisher-Exact test. Continuous variables regarding menstrual pattern between the two groups will be compared by Mann-Whitney U test. Expected results: LNG plus piroxicam has a higher PPP compared to LNG plus placebo. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03614494
Study type Interventional
Source The University of Hong Kong
Contact
Status Completed
Phase Phase 2/Phase 3
Start date August 20, 2018
Completion date October 5, 2022

See also
  Status Clinical Trial Phase
Completed NCT00271583 - Efficacy Trial of CDB 2914 for Emergency Contraception Phase 2/Phase 3
Completed NCT00777556 - Emergency Contraception Actual Use Study Phase 3
Completed NCT00677755 - Medical Abortion for Emergency Contraception Failure N/A
Recruiting NCT06162611 - Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo Phase 4
Completed NCT00411684 - Safety and Efficacy of CDB-2914 for Emergency Contraception Phase 3
Completed NCT01569737 - Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella
Completed NCT03208985 - A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions Phase 3
Completed NCT02078414 - Continued Use of Effective Contraception After Use of Emergency Contraception
Completed NCT01569113 - Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo. Phase 4
Completed NCT01963962 - Study of the Copper IUD or Oral Levonorgestrel and the Levonorgestrel IUD for Women Seeking Emergency Contraception N/A
Recruiting NCT03120728 - Application for the Etonogestrel/Ethinyl Estradiol Ring Phase 4
Active, not recruiting NCT02076217 - Quick Start of Highly Effective Contraception
Not yet recruiting NCT04172584 - Awareness & Use of Emergency Contraception
Completed NCT03395756 - Depot Medroxyprogesterone Acetate as Emergency Contraception Early Phase 1